Ethnic minority groups less informed about cancer symptoms
the ONA take:
According to new findings presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool, United Kingdom, ethnic minorities in England were less informed about cancer symptoms and were less likely to see a doctor when they thought they had a possibly serious symptom.
Researchers at King's College London in London, United Kingdom, analyzed about 50,000 responses from the Cancer Research UK Cancer Awareness Measure, a national population-based survey to investigate levels of cancer awareness. Researchers found that people with a black ethnic background were half as likely as white people to identify unexplained bleeding as a possible cancer symptom.
People of South Asian descent were a one-fourth as likely as white people to identify an explained lump as a possible cancer symptom. In addition, people with South Asian backgrounds were more likely to report embarrassment and low confidence to discuss their symptoms with their doctor, while white people were more concerned about wasting the physician's time.
The findings suggest that more public awareness is needed to help people identify cancer symptoms earlier in disease progression and that people need to be encouraged to discuss unexplained changes in their body with their physician.
Ethnic minorities less informed about cancer symptoms and less likely to see a doctor.
Ethnic minorities in England are less aware of cancer symptoms and more likely to say they wouldn't see the doctor, even when they have a symptom that they think might be serious, according to research being presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
Researchers looked at nearly 50,000 responses to the Cancer Research UK Cancer Awareness Measure* from people across England. They found that ethnic minority groups were consistently less aware of cancer symptoms.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|